Androgen deprivation therapy is the cornerstone of systemic management for prostate cancer but is associated with multiple adverse effects that must be considered during treatment. These effects occur because of the profound hypogonadism that is induced from lack of testosterone or due to the medications used in the treatment or in combination with androgen receptor signaling inhibitors. This article critically reviews the associations between androgen deprivation therapy, androgen receptor signaling inhibitors, and cardiovascular complications such as prolonged QT interval, atrial fibrillation, heart failure, atherosclerosis, coronary heart disease, venous thromboembolism, and peripheral arterial occlusive disease. These unfavorable outcomes reinforce the need for regular cardiovascular screening of patients undergoing androgen deprivation for the management of prostate cancer.
Southern medical journal. 2024 May [Epub]
Richard Orji, Alicia Morgans, Eiman Jahangir, Favor Markson, Ayodeji Ilelaboye, Alan Tan, Tochukwu M Okwuosa
Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Division of Cardiovascular Medicine, Section of Cardio-Oncology, Vanderbilt University Medical Center, Nashville, Tennessee., Department of Internal Medicine, Lincoln Medical Center, Bronx, New York., Department of Internal Medicine, Lagos University Teaching Hospital, Lagos, Nigeria., Division of Hematology-Oncology, Rush University Medical Center, Chicago, Illinois., Division of Cardiovascular Medicine, Section of Cardio-Oncology, Rush University Medical Center, Chicago, Illinois.